Almost 18,000 civilians evacuated from areas of Aleppo controlled by militantsWorld December 10, 7:41
Russian swimmers win 11 sets of medals at FINA World Swimming Championships (25 m)Sport December 10, 7:00
Shiveluch volcano in Russia’s Far East spews ash to 11 km in airWorld December 10, 5:28
Ceasefire agreements enter into force near Damascus, in Idlib province ― mediaWorld December 10, 4:18
Russian pair Tarasova/Morozov win final of ISU Grand Prix of Figure Skating in MarseillesSport December 10, 4:00
Matviyenko to visit UAE to participate in Forum of Women Speakers of ParliamentRussian Politics & Diplomacy December 10, 3:21
Doping samples of all athletes from past three Olympics should be re-analyzed ― lawmakerSport December 10, 2:01
Russia’s figure skater Medvedeva leads with world record after SP at Grand Prix finalsSport December 10, 1:28
Russian energy minister expects OPEC, non member countries to sign agreement on oil outputBusiness & Economy December 10, 0:46
SAN DIEGO, April 25, 2014 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced the commencement of its limited market release of its FDA cleared and CE marked technology SyncVision™, with cases being performed in the U.S. and Europe. SyncVision™ is currently installed in multiple limited market release sites throughout U.S. and Europe.
Volcano's SyncVision™ Technology System is an on-line image processing workstation for coronary catheterizations that allows the physician to navigate simultaneously on an angiogram and on an IVUS image in a single correlated view using co-registration of the Eagle Eye® Platinum catheter with x-ray angiography. SyncVision™ is designed to bring the detailed vessel, lumen and wall structure from angiography and the spatial localization of Volcano's intravascular ultrasound images within the coronary tree together in a co-registered view to facilitate more informed treatment decisions and more efficient, enhanced workflow performance.
"SyncVision™ is an important advancement in clinical IVUS imaging. It allows us to correlate significant IVUS findings with the corresponding spots on the angiogram. This addresses a challenging aspect of current practice in that it can be difficult to identify the precise spot needing treatment in translating the IVUS findings to the angiogram," commented Steven Goldberg, M.D., Director, Cardiac Catheterization Laboratory and Clinical Associate Professor of Medicine at University of Washington Medical Center. "It also allows for simple and precise length measurements to help inform stent selection. Co-registration of different imaging modalities is currently the wave in interventional cardiology, and I think this is one of the most useful and user friendly co-registration formats I have seen. I believe that this truly represents the next generation in IVUS imaging."
"The co-registration with angiography makes of IVUS an entirely new instrument. As a regular IVUS user, I was impressed to see how it helps in making decisions based on intracoronary imaging," commented Javier Escaned, M.D., Consultant Interventional Cardiologist, Hospital Clinico San Carlos. "In addition, the angiographic tools incorporated in SyncVision™ are extremely helpful during coronary interventions. Image stabilization and digital enhancement based not only on cine but also on images under fluoroscopy is a great complement of IVUS in performing accurate stent optimization without geometric mismatch. My impression is that with this system we move into an entirely new era of integration of IVUS and angiography in clinical practice."â€¨
"We are looking forward to sharing the SyncVision™ technology with a global audience next month at the EuroPCR meeting in Paris," said Joe Burnett, Executive Vice President. "We will showcase the technology with working systems at our booth and in the training village, as well as with expert panel discussions and live case presentations."
"We are thrilled about the benefits and precision that the use of SyncVision™ enables in concert with our Eagle Eye Platinum Catheter and the Angio +™ applications. SyncVision™ will change the game in that it empowers easier and better interpretations of both IVUS and angio technologies that are designed to encourage quicker and confident decisions," said Scott Huennekens, President and Chief Executive Officer. "SyncVision™ Technology System demonstrates innovation in design and a commitment to our continued investments in Volcano solutions for our customers. This system further bolsters our portfolio of recent innovative releases with the iFR® modality, CORE™ Precision Guided System, and CORE™ Control Pad—all of which work to help improve patient outcomes and customer productivity."
SyncVision™ is expected to be in full market release later in 2014. Additional product information is available at www.volcanocorp.com.
About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.
Tom Osypian, Volcano Corporation, Media
Neal Rosen, Volcano Corporation, Investor Relations